Anavex Life Sciences Corp. (AVXL) Key Metrics
AVXL valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $121.4M
- Enterprise value
- $99.0M
- P/E (TTM)
- —
- Forward P/E
- 3.9
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.9 10-yr median 7.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.17
AVXL key metrics, FY2016–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsAVXL valuation Price multiples at each fiscal year-end price.
Price / book+103.0%
8.0
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow yield+1.4 pts
−5.1%
FY2025 · hover or tap a bar for each year
FY2016FY2025
AVXL returns How much profit the business earns on the capital it uses.
Return on equity−10.3 pts
−43.1%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Return on assets−9.1 pts
−38.7%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Asset turnover
0.00
FY2025 · hover or tap a bar for each year
FY2016FY2025
AVXL per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
FY2025 · hover or tap a bar for each year
FY2016FY2025
Earnings per share
−$0.54
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow per share
−$0.46
FY2025 · hover or tap a bar for each year
FY2016FY2025
Book value per share−22.8%
$1.11
FY2025 · hover or tap a bar for each year
FY2016FY2025
Shares outstanding+2.2%
85.3M
FY2025 · hover or tap a bar for each year
FY2016FY2025
AVXL financial health Debt, liquidity and how easily interest is covered.
Net debt+$29.6M
−$102.6M
FY2025 · hover or tap a bar for each year
FY2016FY2025
Current ratio+31.0%
11.60
FY2025 · hover or tap a bar for each year
FY2016FY2025
AVXL valuation history
Fiscal year-endToday10-year median
AVXL returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AVXL debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AVXL price vs earnings per share
Share price at year-endEPS (right axis)
AVXL key metrics
FY2016–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $759.1M | $474.1M | $522.6M | $793.7M | $1.25B | $264.8M | $154.5M | $121.9M | $169.1M | $127.6M |
| Enterprise value | $656.5M | $341.9M | $371.6M | $644.6M | $1.10B | $235.5M | $132.4M | $99.0M | $141.6M | $118.4M |
| Price / book | 8.0 | 3.9 | 3.7 | 5.6 | 8.3 | 9.7 | 7.6 | 5.9 | 7.0 | 20.2 |
| Earnings yield | −6.1% | −9.1% | −9.1% | −6.0% | −3.0% | −9.9% | −17.0% | −14.3% | −8.0% | −11.5% |
| Free cash flow yield | −5.1% | −6.5% | −5.3% | −3.1% | −2.4% | −8.0% | −12.0% | −10.3% | −5.3% | −7.2% |
| Dividend yield | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $8.90 | $5.68 | $6.55 | $10.32 | $17.95 | $4.55 | $3.16 | $2.73 | $4.14 | $3.63 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.54 | −$0.52 | −$0.60 | −$0.62 | −$0.54 | −$0.45 | −$0.54 | −$0.39 | −$0.33 | −$0.42 |
| Operating cash flow per share | −$0.46 | −$0.37 | −$0.35 | −$0.32 | −$0.44 | −$0.37 | −$0.38 | −$0.28 | −$0.22 | −$0.26 |
| Free cash flow per share | −$0.46 | −$0.37 | −$0.35 | −$0.32 | −$0.44 | −$0.37 | −$0.38 | −$0.28 | −$0.22 | −$0.26 |
| Cash per share | $1.20 | $1.58 | $1.89 | $1.94 | $2.18 | $0.50 | $0.45 | $0.51 | $0.67 | $0.26 |
| Book value per share | $1.11 | $1.44 | $1.78 | $1.85 | $2.16 | $0.47 | $0.41 | $0.46 | $0.59 | $0.18 |
| Tangible book value per share | $1.11 | $1.44 | $1.78 | $1.85 | $2.16 | $0.47 | $0.41 | $0.46 | $0.59 | $0.18 |
| Dividends per share | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 |
| Shares outstanding | 85.3M | 83.5M | 79.8M | 76.9M | 69.8M | 58.2M | 48.9M | 44.7M | 40.8M | 35.2M |
| Change in shares outstanding | +2.2% | +4.6% | +3.7% | +10.2% | +19.9% | +19.0% | +9.5% | +9.3% | +16.2% | +89.1% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −43.1% | −32.8% | −33.4% | −32.7% | −42.6% | −110.6% | −129.0% | −78.0% | −88.1% | −154.2% |
| Return on assets (ROA) | −38.7% | −29.7% | −30.9% | −30.5% | −38.7% | −87.8% | −105.8% | −66.9% | −72.1% | −118.0% |
| Return on tangible assets | −44.7% | −31.7% | −30.8% | −31.4% | −23.5% | −76.1% | −103.8% | −71.6% | −48.4% | −155.1% |
| Financial health | ||||||||||
| Total debt | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Cash & short-term investments | $102.6M | $132.2M | $151.0M | $149.2M | $152.1M | $29.2M | $22.2M | $22.9M | $27.4M | $9.2M |
| Net debt | −$102.6M | −$132.2M | −$151.0M | −$149.2M | −$152.1M | −$29.2M | −$22.2M | −$22.9M | −$27.4M | −$9.2M |
| Debt / equity | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Debt / assets | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Current ratio | 11.60 | 8.86 | 12.32 | 14.95 | 14.97 | 4.73 | 5.03 | 6.26 | 7.75 | 2.96 |
| Quick ratio | 11.60 | 8.86 | 12.32 | 14.95 | 14.97 | 4.73 | 5.55 | 6.26 | 7.75 | 2.96 |
| Interest coverage | — | — | -49.3 | -53.8 | -10.4 | -6.5 | -190.2 | -620.0 | — | -1.4 |
| Working capital | $94.9M | $120.3M | $141.9M | $142.5M | $150.8M | $27.2M | $20.3M | $20.4M | $24.2M | $6.3M |
| Invested capital | −$7.7M | −$11.9M | −$9.2M | −$6.7M | −$1.3M | −$2.0M | −$1.9M | −$2.4M | −$3.2M | −$2.9M |
| Tangible asset value | $94.9M | $120.3M | $141.9M | $142.5M | $150.8M | $27.2M | $20.3M | $20.5M | $24.3M | $6.3M |
| Net current asset value | $94.9M | $120.3M | $141.9M | $142.5M | $150.8M | $27.2M | $20.3M | $20.4M | $24.2M | $6.3M |
| Graham net-net per share | $1.10 | $1.42 | $1.76 | $1.84 | $2.12 | $0.44 | $0.36 | $0.46 | $0.58 | $0.17 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / depreciation | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.41 |
| Efficiency | ||||||||||
| Days payables outstanding | — | — | — | — | — | — | — | — | — | 806,302.3 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.6M | $2.6M | $3.0M | $6.2M | $7.0M | $3.7M | $2.3M | $940,052 | $44,548 | $78,094 |
| Average payables | $6.9M | $7.0M | $4.1M | $4.3M | $4.4M | $3.8M | $3.2M | $3.3M | $3.3M | $2.8M |
| Average inventory | — | — | — | — | $16,365 | — | −$1.3M | $0 | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from AVXL's annual financial statements (latest annual report filed November 25, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AVXL valuation and financial ratios
Anavex Life Sciences earned a return on equity of −43.1% in fiscal 2025. The share count rose 142.6% from 35.2M to 85.3M over 9 years.
See the AVXL income statement, the AVXL chart for price history, or the AVXL stock overview for the latest quote and news.
AVXL key metrics FAQ
What is Anavex Life Sciences's return on equity?
Anavex Life Sciences's return on equity (ROE) was −43.1% in fiscal 2025: net income of -$46.4 million on average shareholders' equity of $107.6 million.
What is Anavex Life Sciences's free cash flow yield?
Anavex Life Sciences generated -$39.0 million of free cash flow in fiscal 2025, a free cash flow yield of −5.1% on its market value at year-end ($759.1 million).
What is Anavex Life Sciences's current ratio?
Anavex Life Sciences's current ratio was 11.60 at the end of fiscal 2025: current assets were 11.60 times current liabilities.